Tags

Type your tag names separated by a space and hit enter

Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.
Eur J Neurol. 2005 Dec; 12(12):956-63.EJ

Abstract

The treatment of Parkinson's disease (PD) with l-DOPA leads to involuntary movements (dyskinesias). This 6-month observational study in three European countries in PD patients with various degrees of motor complications examined the effects of dyskinesias on the quality of life (QoL) of patients and health care costs. Retrospective and prospective health economic data were collected, and QoL of patients was measured using the Short Form-36 (SF-36) and the PD Quality of Life (PDQL) Scale. Regression analysis was used to estimate the adjusted effects of dyskinesias on QoL and costs, whilst accounting for the potentially confounding effects of disease progression, motor fluctuations and country. Increasing dyskinesia scores on either the Unified PD Rating Scale or the Goetz Dyskinesia Rating Scale were associated with significant reductions in QoL scores on the SF-36 and PDQL Scale. Increasing dyskinesia severity was also associated with increased depression scores on the Montgomery-Asberg Depression Rating Scale along with significant increases in health care costs. The effects of dyskinesia on QoL, depression and costs decreased but remained significant after adjustment for the confounding effects of disease progression and motor fluctuations. In conclusion, dyskinesias may adversely affect QoL and increase health care costs in patients with PD. Future studies should evaluate the potentially beneficial effects in terms of QoL and health care costs of strategies to delay the onset of, or the treatment of, dyskinesias.

Authors+Show Affiliations

CEMKA-EVAL, Bourg-la-Reine, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16324089

Citation

Péchevis, M, et al. "Effects of Dyskinesias in Parkinson's Disease On Quality of Life and Health-related Costs: a Prospective European Study." European Journal of Neurology, vol. 12, no. 12, 2005, pp. 956-63.
Péchevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol. 2005;12(12):956-63.
Péchevis, M., Clarke, C. E., Vieregge, P., Khoshnood, B., Deschaseaux-Voinet, C., Berdeaux, G., & Ziegler, M. (2005). Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. European Journal of Neurology, 12(12), 956-63.
Péchevis M, et al. Effects of Dyskinesias in Parkinson's Disease On Quality of Life and Health-related Costs: a Prospective European Study. Eur J Neurol. 2005;12(12):956-63. PubMed PMID: 16324089.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. AU - Péchevis,M, AU - Clarke,C E, AU - Vieregge,P, AU - Khoshnood,B, AU - Deschaseaux-Voinet,C, AU - Berdeaux,G, AU - Ziegler,M, AU - ,, PY - 2005/12/6/pubmed PY - 2006/1/19/medline PY - 2005/12/6/entrez SP - 956 EP - 63 JF - European journal of neurology JO - Eur J Neurol VL - 12 IS - 12 N2 - The treatment of Parkinson's disease (PD) with l-DOPA leads to involuntary movements (dyskinesias). This 6-month observational study in three European countries in PD patients with various degrees of motor complications examined the effects of dyskinesias on the quality of life (QoL) of patients and health care costs. Retrospective and prospective health economic data were collected, and QoL of patients was measured using the Short Form-36 (SF-36) and the PD Quality of Life (PDQL) Scale. Regression analysis was used to estimate the adjusted effects of dyskinesias on QoL and costs, whilst accounting for the potentially confounding effects of disease progression, motor fluctuations and country. Increasing dyskinesia scores on either the Unified PD Rating Scale or the Goetz Dyskinesia Rating Scale were associated with significant reductions in QoL scores on the SF-36 and PDQL Scale. Increasing dyskinesia severity was also associated with increased depression scores on the Montgomery-Asberg Depression Rating Scale along with significant increases in health care costs. The effects of dyskinesia on QoL, depression and costs decreased but remained significant after adjustment for the confounding effects of disease progression and motor fluctuations. In conclusion, dyskinesias may adversely affect QoL and increase health care costs in patients with PD. Future studies should evaluate the potentially beneficial effects in terms of QoL and health care costs of strategies to delay the onset of, or the treatment of, dyskinesias. SN - 1351-5101 UR - https://www.unboundmedicine.com/medline/citation/16324089/Effects_of_dyskinesias_in_Parkinson's_disease_on_quality_of_life_and_health_related_costs:_a_prospective_European_study_ L2 - https://doi.org/10.1111/j.1468-1331.2005.01096.x DB - PRIME DP - Unbound Medicine ER -